Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tryp Therapeutics Inc (OP: TRYPF )

N/A UNCHANGED
Last Price Updated: 3:17 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tryp Therapeutics Inc

< Previous 1 2 3 4 5 Next >
Is Psilocybin Therapy A Potential Treatment For Fibromyalgia & Binge Eating Disorder?
Clinical-stage developer of psychedelic compounds Tryp Therapeutics Inc. (OTCQB: TRYPF) filed two provisional patent applications - one for psilocybin therapy for fibromyalgia and another expanding... 
Via Benzinga
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Methodical Expansion of Its IP Portfolio
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Appoints Veteran Finance Exec as CFO
Via Investor Brand Network
Psychedelics Companies Share Corporate Updates: Numinus, Delix, Tryp And Small Pharma
Numinus Updates On New Acquisition’s Integration And Provides Client Financing Options 
Via Benzinga
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with IMS Investor Relations for Consulting, Communications and Outreach Services
Via Investor Brand Network
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Expands IP Portfolio with New Provisional Patent Application
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Appoints Health Care and Biotech Expert as New Chief Operating Officer
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider. 
Via Benzinga
Clinical Trials Of Psilocybin Treatment For Overeating Disorder Are Ready, Here's What Results Show So Far
Tryp Therapeutics Inc. (OTCQB: TRYPF) is a clinical-stage biotech company focused on developing psilocybin-based compounds for ill-treated diseases. 
Via Benzinga
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Results from Phase II Binge Eating Disorder Clinical Trial
Via Investor Brand Network
These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry
In the nascent industry of medical psychedelics, drug development is the name of the game. This subset of biotech, poised to become a $100 billion industry according to Canaccord Genuity, bases its... 
Via Benzinga
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Names New Independent Director to Board
Via Investor Brand Network
Psyched: Elon Musk Praises Psychedelics Over Antidepressants, Field Trip To Split In Two, Colorado MDMA Bill Moves Forward
The world’s richest man gave another public nod to psychedelics medicine in favor of traditional mental health solutions. 
Via Benzinga
Could Magic Mushrooms Be A Solution For Overeating? New Clinical Trial Intends To Find Out
Psilocybin, the active ingredient in “magic mushrooms,” could be part of the solution for people struggling with binge eating disorder, a condition characterized by recurring episodes of eating large... 
Via Benzinga
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Doses First Patient in Clinical Trial for Psilocybin-Assisted Therapy Targeting BED
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Initiates Enrollment for Study to Evaluate TRP-8802 to Treat Binge Eating Disorder
Via Investor Brand Network
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces New Board Appointment, Closing of First Tranche of Private Placement
Via Investor Brand Network
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Upsizing of Private Placement
Via Investor Brand Network
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Q1 2022 Financial Numbers
Via Investor Brand Network
BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces January 2022 Health Care Conference Schedule
Via Investor Brand Network
FDA Approves Psilocybin For Binge Eating Study By Tryp Therapeutics
Tryp Therapeutics (CSE:TRYP) (OTCQB: 
Via Benzinga
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Advancement of Binge-Eating Clinical Trial
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases FY 2021 Updates, Results
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Set to Proceed with its Phase 2a Fibromyalgia Study Following FDA Confirmation
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Clinical Trials, Focus Puts It ‘In Pretty Rarefied Air’
Via Investor Brand Network
Exposures Product Safety
FDA green lights Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Psychedelic Drug Trial for Treating Fibromyalgia, After Completing IND Process
Via Investor Brand Network
Topics Law Enforcement
Exposures Legal Product Safety
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at 2nd Annual H.C. Wainwright Psychedelics Conference
Via Investor Brand Network
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Receives Green Light from FDA for Clinical Study in Fibromyalgia
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Eager to Initiate ‘One of the First Evaluations of Psilocybin to Treat Fibromyalgia’
Via Investor Brand Network
Exposures Product Safety
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Psilocybin Drug Program for the Treatment of Pain and Eating Disorders Takes On Special Meaning Leading Up To The Holidays
Via Investor Brand Network
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.